High-dose cytarabine in induction treatment improves the outcomes of adult patients with acute myeloid leukemia (AML). In particular, high-dose cytarabine produces higher remission and survival rates than the standard-dose cytarabine in patients younger than age 46 years.
“The most commonly administered induction regimen for patients with AML is a daily dose of 100 to 200 mg/m2 of cytarabine for 7 to 10 days in combination with 3 days of an anthracycline. This treatment has been shown to result in complete remission rates of 60% to 80% depending on age of the patient as well as genetic and molecular characteristics of the disease. Up until now, however, we did not have clear consensus on the benefit of higher dosages of cytarabine,” explained lead author Roelef Willemze, MD, PhD, of the Leiden University Medical Centre in the Netherlands.
This trial, AML-12, was conducted by the European Organisation for Research and Treatment of Cancer (EORTC) and GIMEmA (Gruppo Italiano Malattie Ematologiche dell’ Adulto) and the results were published in the Journal of Clinical Oncology (2013; doi:10.1200/JCO.2013.51.8571).
The AML-12 included 1,942 newly diagnosed patients with AML age 15 to 60 years and compared remission-induction treatment with daunorubicin, etoposide, and either standard-dose (100 mg/m2 per day by continuous infusion for 10 days) or high-dose (3,000 mg/m2 every 12 hours by 3-hour infusion on days 1, 3, 5, and 7) cytarabine. Patients in complete remission received a single consolidation cycle containing daunorubicin and intermediate-dose cytarabine.
At a median follow-up of 6 years, overall survival was 38.7% for patients receiving standard-dose and 42.5% for those receiving high-dose cytarabine (log-rank test P=0.06; multivariable analysis P=0.009).
For patients younger than 46 years, survival was 43.3% with standard-dose treatment and 51.9% with high-dose treatment (P=0.009; multivariable analysis P=0.003). Survival for patients age 46 to 60 years was 33.9% and 32.9%, respectively (P=0.91).
Complete remission rates were 72.0% for standard-dose and 78.7% for high-dose (P<0.001). Patients younger than 46 years had complete remission rates of 75.6% and 82.4%, respectively, (P=0.01), whereas patients 46 years and older had rates of 68.3% and 74.8%, respectively (P=0.03).
The intergroup EORTC-GIMEMA AML-12 Trial was supported by an educational grant from the EORTC Charitable Trust and was conducted at 63 sites in 10 countries: Austria, Belgium, Croatia, Czech Republic, France, Italy, Portugal, Slova